|
|
||||||||
1 From the Molekulargenetisches Labor and 2 Abteilung für Pathophysiologie des Sehens und Neuroophthalmologie, Universitäts-Augenklinik, Tübingen, Germany; and 3 Abteilung Neuroophthalmologie und Schielbehandlung, Universitäts-Augenklinik Freiburg, Freiburg, Germany.
| Abstract |
|---|
|
|
|---|
METHODS. Segregation analysis was performed in a cross-sectional study by determining the level of heteroplasmy in blood leukocytes of 23 LHON patients and unaffected carriers from four unrelated families. One family comprising two affected and three unaffected carriers was followed over 5.5 years for a longitudinal segregation analysis of heteroplasmy. The percentage of mutant mtDNA was determined using a novel procedure of fluorescence-based primer extension and restriction fragment length polymorphism analysis. The prevalence of heteroplasmy was assessed by determining the number of genealogically unrelated LHON pedigrees with heteroplasmic maternal family members from the LHON patient records of the Department of Ophthalmology, University of Tübingen, Germany.
RESULTS. The authors observed a marked variability in the degree of heteroplasmy levels within each pedigree and a tendency toward a higher mutant allele frequency in offspring generations. Disease expression was correlated with higher levels of mutant mtDNA molecules. Longitudinal analysis revealed no statistically significant decrease in the heteroplasmy level in the family studied but a reduction of 11% and 12% in one affected and one unaffected individual, respectively. In 167 genealogically unrelated LHON families the prevalence of heteroplasmy was 5.6%, 40%, and 36.4% for the 11778, 3460, and 14484 LHON mutations, respectively.
CONCLUSIONS. Cross-sectional studies of heteroplasmy for the 3460 LHON mutation suggest that the genotype shifts toward a higher mutational load in offspring generations. Long-term decrease in the blood mutant load in single cases indicates negative selection of the mutant allele in the hematopoietic cell system. The prevalence of heteroplasmy varies significantly between the different primary LHON mutations, suggesting genotypical differences in disease expression.
| Introduction |
|---|
|
|
|---|
We here report the results of segregation analysis of the heteroplasmic LHON mutation at nucleotide 3460 in 23 LHON patients and unaffected carriers from four families. In one family, comprising three healthy and two affected individuals carrying the mutation, a longitudinal analysis of the blood heteroplasmy levels was carried out over a period of 5.5 years. The degree of heteroplasmy, that is, the percentage of mutant mtDNA, was determined by means of a novel procedure of fluorescence-based primer extension and restriction fragment length polymorphism (RFLP) analysis (Jacobi FK et al., unpublished results, 2001).
Furthermore, a review of our repository of LHON family records revealed the prevalence of heteroplasmy in genealogically unrelated LHON families positive for either one of the three common LHON mutations.
| Methods |
|---|
|
|
|---|
In one LHON family comprising a mother, her three sons, and a daughter, a longitudinal study was carried out over 5.5 years. Two sons had been diagnosed with LHON by clinical examination in the mid-1980s at the Department of Ophthalmology, University of Freiburg, Germany, whereas the other family members were visually asymptomatic. One son gradually recovered full central vision over a 5-year period (124-II:2), whereas his brother remained legally blind (124-II:1). Blood was first collected for LHON analysis in April 1994 from the offspring and in April 1996 from the mother. At that time, a second blood sample was obtained from individuals 124-II:2 and 124-II:3. Additional blood samples from all family members were collected in December 1999.
For the assessment of heteroplasmy prevalence, records of patients and unaffected maternal family members from the LHON repository at the Department of Ophthalmology, University of Tübingen were reviewed, and the degree of heteroplasmy was estimated by agarose gel electrophoresis after conventional methods of PCR/RFLP analysis.
All investigations complied with the regulations set out in the Declaration of Helsinki, and informed consent and fall institutional review board approval were obtained.
DNA Isolation and PCR
Total DNA was extracted by a standard technique from whole blood
samples.9
An mtDNA fragment encompassing np3393 to np4203
was amplified in a 50 µl PCR containing 50 ng of blood
leukocyte DNA, 10 pmol of L-Strand and H-Strand primers, 200 µM of
each dNTP, 10 mM Tris-HCl (pH 8.6), 50 mM KCl, 0.001% gelatin,
and 0.25 U AmpliTaq DNA polymerase (PE Biosystems, Weiterstadt,
Germany). The sequence of the L-strand primer (nucleotides 33933414)
was 5'-CTATATACAACTACGCAAAGGC-3' and that of the H-strand (nucleotides
42034186) 5'-TGCTAGGGTGAGTGGTAG-3'. The cycling protocol was
performed an a GeneAmp PCR System 9600 Thermal Cycler (PE Biosystems)
using the following reaction conditions: an initial 5 minutes
denaturation at 96°C, followed by 30 cycles of 94°C for 1 minute,
53°C for 1 minute, and 72°C for 1 minute, and a final 5-minute
extension step at 72°C. PCR products were purified by agarose gel
electrophoresis, and DNA was recovered using the QIAquick gel
extraction kit (Qiagen, Hilden, Germany). The purified PCR product was
eluted from the column in 50 µl of 10 mM Tris-HCl, pH 8.5. DNA from
each sample was amplified in at least five independent reactions.
Fluorescence-Based Primer Extension and RFLP Analysis
The quantitation procedure for the mtDNA mutation at np3460 is
described in detail elsewhere (Jacobi FK et al., unpublished
results, 2001). This is an improvement on the traditional PCR/RFLP
method used in analysis of point mutations, the main modifications
being (i) the inclusion of a fluorescence-based primer extension step
using Vent (exo-) DNA polymerase to avoid quantitation errors due to
heteroduplex formation in PCR, (ii) the quantitation of DNA fragments
by polyacrylamide gel electrophoresis and automated spectrofluorometry
an a DNA sequencer equipped with GENESCAN analysis software, and (iii)
estimation of the percentage of mutant mtDNA using a simple
mathematical model based on an in-tube digestion reaction of a
homologous control DNA fragment. In contrast to the traditional
PCR/RFLP assay, the present approach does not depend an complete
endonuclease restriction, Instead, the proportion of uncleaved allele
that comigrates with the "truly uncleavable" allele in incomplete
digestion is estimated and subtracted from the latter, based on
restriction efficiency determined by the homologous control.
The assay uses a polyacrylamide gel-purified 5'-JOElabeled nested primer with the sequence 5'-GATCAGAGGATTGAGTAAACGC-3' (nucleotides 36623640 of the H-strand) and the Vent (exo-) DNA polymerase in the primer extension reaction. The primer extension products, a 269-bp and a 281-bp fragment for the sample and the control, respectively, are restricted with the endonuclease BsaHI, which cleaves the wild-type mtDNA into 204- and 65-bp fragments and the control DNA into 216- and 65-bp fragments, respectively. The mutant mtDNA remains uncleaved. All enzymes used in this assay were purchased from New England Biolabs (Schwalbach, Germany).
The level of heteroplasmy was measured in at least five independent reactions and averaged for each DNA sample using PCR-amplified DNA as a template.
Multiple Cloning and RFLP Analysis of PCR Products
Gel-extracted PCR products from reactions using the
above-mentioned primers and conditions were cloned into a pCR
2.1 vector using the TA Cloning Kit (Invitrogen,
Groningen, The Netherlands). Recombinant DNA was isolated from
bacterial colonies by a standard alkaline lysis minipreparation, and 50
ng of plasmid DNA were digested overnight with BsaHI.
Wild-type and mutant-type clones were differentiated by a four- and
three-band pattern, respectively, an agarose gel electrophoresis.
Clones showing a mixed digestion pattern were found in some instances
and excluded from analysis. A total of 80 colonies were processed for
each sample, and the percentage of mutant-type clones was determined.
Statistical Analysis
The statistical significance of changes in the heteroplasmy
ratio over time was determined using the Wilcoxon matched-pairs signed
rank test and a representative value from repeated measurements of each
dated DNA sample. The difference in heteroplasmy rate between the three
primary LHON mutations was tested for statistical significance using
2 statistics for 2 x 3 cross-tabulations
(both SPSS 8.0 for Windows; SPSS GmbH Software, Munich, Germany).
| Results |
|---|
|
|
|---|
Quantitative assessment of heteroplasmy revealed a marked variability of degrees both among siblings and between different generations of a family (Fig. 1) . The analysis of the transmission pattern in the four families studied demonstrated an average increase in the heteroplasmy ratio. The affection status correlated roughly with the level of heteroplasmy, higher levels being found in LHON patients than in their unaffected relatives. However, a blood heteroplasmy level of only 26% was found in one patient of LHON family 192.
|
|
| Discussion |
|---|
|
|
|---|
The results of the cross-sectional study demonstrate a marked genotypic variability and a poor correlation between the level of heteroplasmy in white blood cells and disease expression, shown most strikingly in one male patient of family 192 with a blood mutation load of only 26%. This is extremely low, in view of the previously estimated threshold for expression of 75% to 80%1 and probably reflects the variation of the mutant allele frequency in different tissues arising from random segregation of wild-type and mutant mtDNA during embryogenesis. In a postmortem study of a female LHON patient carrying the 11778 mutation, Howell et al.11 reported a heteroplasmy level of 33% in the white blood cell fraction compared with 95% and 100% in the optic nerve and retina, respectively. In a study by Black et al.12 the mutant mtDNA fraction was only 15% in white blood cells of one patient with the 3460 mutation.
The increase in the heteroplasmy level in subsequent generations observed in our study has been attributed in the past to an ascertainment bias, according to which only families with a high average heteroplasmy level are studied, which through random segregation creates a genetic shift toward homoplasmy of the mutant allele.6 Interpreting our observed decrease in the level of heteroplasmy over a limited time span in two individuals in terms of a lifelong reduction of mutant allele frequency, the suspected intergenerational shift of heteroplasmy toward higher mutant allele frequency might be explained in part by the fact that in pedigree analyses members of the parental generation are examined at a greater age, when literally "blood stem cells have had more time to sort out the mutant allele."
The data from longitudinal segregation analysis of five individuals heteroplasmic for the 3460 mutation fail to show a statistically significant decrease in blood heteroplasmy. However, the low P value obtained from statistical analysis suggests the possibility of a systematic decrease in blood heteroplasmy over time in a larger study population. The marked reduction in mutant load in one affected and one unaffected individual is a remarkable finding, contrasting with the apparently stable heteroplasmy levels in the other family members. It is important in that it suggests a negative selection of the mutant allele in the hematopoietic stem cells or some committed progenitor cells of white blood cells in selected individuals carrying the heteroplasmic mtDNA mutation. It has long been assumed that blood heteroplasmy of LHON mutations segregates stably over an extended period,7 8 but only recently Howell et al.13 reported a reduction in heteroplasmy levels of LHON patients. Earlier studies may have failed to detect negative selection because it is not an ubiquitous event in LHON mutation carriers or because the quantitating procedures used were not sufficiently accurate or the follow-up period was too short. In subject II:3 of family 124, we noted a slight change between April 1994 (30%) and April 1996 (29%), but an 11% decrease in December 1999. This suggests that a decrease in mutant allele frequency may occur at a variable rather than a constant rate, which would be in line with the subtle change observed in other family members. The results presented in the longitudinal study by Howell et al.13 do not rule out the possibility of the 3460 mutant alleles decrease in heteroplasmy being discontinuous rather than continuous, and they show such a time course in at least 2 of 8 individuals. It may therefore be inappropriate to express mutant load decreases generally as mean changes per year as has previously been done.
One proposed mechanism for the long-term reduction in mutant load is that individual hematopoietic stem cells homoplasmic for wild-type mtDNA will divide faster than cells with a significant proportion of mutant mtDNA and thus shift the stem cell population toward wild-type over time.13 The advantage of this hypothesis is that it explains the decrease in mutant load without preferential replication, segregation, or partitioning of the wild-type necessarily being involved as others have proposed.14 Another possible mechanism could be that preferential mtDNA degradation rather than synthesis causes a decrease in the mutant load over time. In view of the poor repair mechanisms of mtDNA, it has been suggested that preferential degradation has the function of removing defective mtDNA.15 Mitochondrial degradation or autophagy is part of the physiological life cycle of mitochondria and is probably mediated by the process of so-called mitochondrial permeability transition, a critical step in the events leading to cell apoptosis, and is induced, among other things, by reactive oxygen species (ROS). Given the increase in ROS formation caused by primary LHON mutations, this pathway could possibly account for long-term reduction in the mutant load of white blood cells.16
One question raised by the present study is what implication the possibility of negative selection in dividing cells could have for the mutant load in retinal ganglion cells in LHON. This issue is particularly intriguing in the light of the spontaneous visual recovery observed in a small number of LHON cases, which occasionally occurs up to several years after visual loss. This indicates that the impairment of oxidative phosphorylation associated with LHON mutations may be sufficient to cause retinal ganglion cell dysfunction but not irreversible cell damage under certain circumstances. A recent study suggests that with more refined testing methods, partial improvement of visual function may be found to be more widespread in patients with the 11778 mutation in LHON than was previously thought.17 Though clearly other regulating factors, such as hormonal, environmental, and tissue-specific factors are likely to be responsible for visual recovery, it is not erroneous to assume that a selective mechanismeither replicative, degradative, or bothcould be operating in retinal ganglion cells of heteroplasmic LHON cases. Knowledge of the factors regulating mtDNA maintenance at the cellular and mitochondrial level in a cell- and tissue-specific manner is still incomplete.18 If there is an inherent randomness in mitochondrial kinetics, genotypic shifts should theoretically evolve at a faster rate in mitotically active tissue than in postmitotic tissue, because mitotic segregation and proliferation of mtDNA segregating units (whether as a single mtDNA molecule or "mitochondrial nucleoid") at the intercellular level would intensify replicative segregation at the intracellular level.
Mitochondrial genotypic stability, together with increases and decreases in the mutant allele frequency in tRNA and protein encoding genes, has been reported in several longitudinal studies.6 19 20 21 Kawakami et al.19 described a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), in whom muscle weakness improved gradually with age and was paralleled by a decrease in the population of mutant genomes. However, there is a general trend emerging that suggests that pathogenic mtDNA mutations undergo segregational loss in dividing cells, such as those of the hematopoietic cell system,13 20 but not in nondividing cells such as neurons.6 22 23 Thus, despite the many discrepancies observed, the issue of potential selective mechanisms in target tissue of LHON merits further investigation on account of its potential clinical importance.
The second issue dealt with in the present study is the prevalence of heteroplasmy in genealogically unrelated LHON pedigrees. In reviewing our records of LHON families, we found a significant, sevenfold higher prevalence of heteroplasmy in families carrying the 3460 (40%) or 14484 (36.4%) LHON mutation as opposed to the 11778 LHON mutation (5.6%), which is estimated to account for 50% to 70% of the LHON cases. Although an ascertainment bias among the primary LHON mutations cannot be totally excluded, owing to an element of bias in the selection of the families studied, it is unlikely to have had a profound impact on these estimates because of the randomness of the ascertainment process. The heteroplasmy prevalence for the less common 3460 and 14484 LHON mutations, each accounting for approximately 15% of cases,24 is not explicitly evident from literature data, whereas the 11778 mutation has repeatedly been reported as being heteroplasmic in approximately 14% of LHON families.2 3 The 3460 and the 14484 mutations have been found to be homoplasmic in some cases and heteroplasmic in others, with the 14484 mutation being more commonly associated with homoplasmy.24 25 Harding et al.26 reported heteroplasmy in 5 (7.6%) of 66 families carrying the 11778 mutation, in 2 (25%) of 8 families with the 3460 mutation and in 2 (18%) of 11 families with the 14484 mutation (one of which was additionally homoplasmic for the 11778 mutation). The authors also found heteroplasmy in LHON cases with the 3460 and 14484 mutation more frequently than with the 11778 mutation, however, at a low percentage (4%). Howell et al.27 studied 18 LHON patients and unaffected matrilineal relatives from six families carrying the 3460 mutation and found heteroplasmy in 2 (33%) of 6 families. Two (22%) of 9 LHON patients studied were heteroplasmic for the mutation. In contrast, Huoponen et al.28 excluded heteroplasmy in 10 LHON patients and healthy matrilineal relatives from three families carrying the 3460 mutation. Oostra et al.29 reported heteroplasmy in 2 (13%) of 15 compared with 2 (100%) of 2 families carrying the 11778 and 3460 mutations, respectively. The reason for the discrepancy in the reported heteroplasmy rate for the 3460 mutation, and possibly for the less reported 14484 mutation, is probably the small number of families analyzed in most studies, some pedigrees being represented only by single cases.27 In our review of LHON pedigrees, which contains the largest collective so far described, we corroborate the finding of a higher level of heteroplasmy for the 3460 and 14484 mutations than for 11778.
This variation in levels of heteroplasmy may relate to both genetic and biochemical factors associated with the primary LHON mutations, such as their transmission and segregation kinetics, their tendency to coexist with certain mtDNA lineages, or the severity of the oxidative phosphorylation defect underlying disease expression. First, little is known about the differences in transmission and segregation kinetics of the various primary LHON mutations. Our study results confirm previous findings associated with the 11778 and 3460 mutations, suggesting that there are substantial intrafamilial variations in mutant allele frequency30 31 as well as a genetic drift toward a higher mutant allele frequency in offspring generations1 6 and a possible segregation of mutant mtDNA under negative selection.13 A notable point of distinction among the primary LHON mutations is the high percentage of singleton cases (58%) with the 11778 mutation,2 which together with the higher rate of homoplasmy could be brought about by a rapid replicative drift toward the mutant mtDNA genome.32
Second, the coexistence of primary LHON mutations and certain mtDNA lineages may indirectly account for the observed difference in the heteroplasmy rate in LHON pedigrees. Although the primary LHON mutations have appeared in a large number of different mtDNA haplogroups, suggesting de novo mutational events in most pedigrees, it is also evident from phylogenetic studies that the primary LHON mutations differ in their preferential association with haplogroup J, which occurs in approximately 9% of the general European population.25 33 34 The latter is partially defined by variants or so-called secondary mutations, such as 13708 G-A and 4216 T-C or, to a lesser degree, the 15257 G-A mutation, which may account for this haplogroups predilection toward an increased disease expression of primary LHON mutations. The strongest preferential association with haplogroup J has been demonstrated for the 14484 mutation (80%), followed by the 11778 mutation (37%).35 The 3460 mutation represents an extreme in that it appears to be distributed randomly among all mtDNA haplogroups.36 This implies that the 3460 mutation does not require additional, secondary mutations for disease expression and should thus be the most susceptible to selective pressure.37 Under the assumption that the kinetics of mitochondrial genetics are predominantly determined by random genetic drift, heteroplasmy can be considered an intermediate condition in the transition from one homoplasmic sequence to another, although this has not been observed in all mutational events38 39 or in silent polymorphisms.40 Hence, heteroplasmy also implies that mutations have occurred relatively recently. This is supported by phylogenetic analyses of LHON disease that have revealed high incidences of heteroplasmy (32.1% for the 11778 mutation and 85.7% for the 3460 mutation).36 Accordingly, the predominance of homoplasmy of the 3460 mutation in some studies27 may suggest a more distant origin on a generational time scale.
Third, in addition to differences in the genetic basis of the various primary LHON mutations, there are marked differences in clinical presentation and biochemical defects. The mildness of the clinical course and the rate of spontaneous visual recovery correlate with the type of mutation, increasing from mutation 11778 through 3460 to 14484. A recent functional analysis of the primary LHON mutation has demonstrated that the biochemical defect is more severe in the 3460 than in 11778 and mildest in the 14484 mutation.16 This fits well with the theory that heteroplasmy is a more important determinant in the 3460 than in the 11778 LHON mutation, although it does not explain the proportionally high rate of heteroplasmy observed in our LHON families carrying the 14484 mutation. The threshold for disease expression in heteroplasmic cases with the 14484 mutation may be lowered by a synergistic effect of haplotype J and the 14484 mutation on energy metabolism deficiency in LHON.41 However, at least with respect to the 11778 mutation, the augmentation of disease expression by secondary LHON mutations has been the subject of much controversy.3 42 43 44
In summary, the key findings of the present study, namely the possible operation of negative selective mechanisms on the 3460 mutant allele in dividing cells and the higher prevalence of blood heteroplasmy in LHON families carrying the 3460 or 14484 mutation compared with the 11778 mutation, provide new insights into the kinetics of disease-related mitochondrial genetics and suggest genotypical differences in disease expression. Drawing on current knowledge of mitochondrial genetics related to LHON, we discuss the possible reasons and implications of these observations.
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication August 14, 2000; revised December 22, 2000; accepted January 24, 2001.
Commercial relationships policy: N.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be marked
"advertisement" in accordance with 18 U.S.C.
1734
solely to indicate this fact.
Corresponding author: Felix K. Jacobi, Universitäts-Augenklinik Giessen, Friedrichstraße 18, 35392 Giessen, Germany. felix.k.jacobi{at}augen.med.uni-giessen.de
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. Kaare, A. Gotz, V.-M. Ulander, S. Ariansen, R. Kaaja, A. Suomalainen, and K. Aittomaki Do mitochondrial mutations cause recurrent miscarriage? Mol. Hum. Reprod., May 1, 2009; 15(5): 295 - 300. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. D. Jeppesen, M. Schwartz, A. L. Frederiksen, F. Wibrand, D. B. Olsen, and J. Vissing Muscle Phenotype and Mutation Load in 51 Persons With the 3243A>G Mitochondrial DNA Mutation Arch Neurol, December 1, 2006; 63(12): 1701 - 1706. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |